Cargando…

Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy

FOLFOX (5‐fluorouracil, leucovorin and oxaliplatin) is one of the main chemotherapy regimens for colorectal cancer (CRC), but only half of CRC patients respond to this regimen. Using gene expression profiles of 96 metastatic CRC patients treated with FOLFOX, we first selected gene pairs whose within...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Jun, Cheng, Jun, Guan, Qingzhou, Yan, Haidan, Li, Yawei, Zhao, Wenyuan, Guo, Zheng, Wang, Xianlong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942442/ https://www.ncbi.nlm.nih.gov/pubmed/31785020 http://dx.doi.org/10.1111/cas.14263

Ejemplares similares

Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer
por: Guan, Qingzhou, et al.
Publicado: (2018)

A qualitative transcriptional signature for the early diagnosis of colorectal cancer
por: Guan, Qingzhou, et al.
Publicado: (2019)

A Qualitative Transcriptional Signature for the Risk Assessment of Precancerous Colorectal Lesions
por: Guan, Qingzhou, et al.
Publicado: (2021)

Robust transcriptional signatures for low-input RNA samples based on relative expression orderings
por: Liu, Huaping, et al.
Publicado: (2017)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk of Stage I–III Bladder Cancer Patients After Surgical Resection
por: Li, Yawei, et al.
Publicado: (2019)

A robust qualitative transcriptional signature for the correct pathological diagnosis of gastric cancer
por: Yan, Haidan, et al.
Publicado: (2019)

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
por: Chen, Yanhua, et al.
Publicado: (2020)

The Effects of Age, Cigarette Smoking, Sex, and Race on the Qualitative Characteristics of Lung Transcriptome
por: Guan, Qingzhou, et al.
Publicado: (2020)

Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer
por: Cai, Hao, et al.
Publicado: (2015)

A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings
por: Ao, Lu, et al.
Publicado: (2018)

Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis
por: Yan, Haidan, et al.
Publicado: (2017)

Two novel qualitative transcriptional signatures robustly applicable to non‐research‐oriented colorectal cancer samples with low‐quality RNA
por: Cheng, Jun, et al.
Publicado: (2021)

Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning
por: He, Jun, et al.
Publicado: (2017)

Identification and characterization of genes with absolute mRNA abundances changes in tumor cells with varied transcriptome sizes
por: Cai, Hao, et al.
Publicado: (2019)

Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples
por: Chen, Rou, et al.
Publicado: (2016)

Shared liver-like transcriptional characteristics in liver metastases and corresponding primary colorectal tumors
por: Cheng, Jun, et al.
Publicado: (2018)

Biased Influences of Low Tumor Purity on Mutation Detection in Cancer
por: Cheng, Jun, et al.
Publicado: (2020)

A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer
por: Fu, Yelin, et al.
Publicado: (2019)

Identification of the predictive genes for the response of colorectal cancer patients to FOLFOX therapy
por: Lin, Hengjun, et al.
Publicado: (2018)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Qualitative Transcriptional Signature for the Pathological Diagnosis of Pancreatic Cancer
por: Zhou, Yu-Jie, et al.
Publicado: (2020)

A Qualitative Transcriptional Signature for Predicting CpG Island Methylator Phenotype Status of the Right-Sided Colon Cancer
por: You, Tianyi, et al.
Publicado: (2020)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
por: Okuno, Keisuke, et al.
Publicado: (2023)

FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms
por: Lu, Wei, et al.
Publicado: (2020)

Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer
por: Yan, Haidan, et al.
Publicado: (2019)

miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
por: Hon, Kha Wai, et al.
Publicado: (2018)

Circumvent the uncertainty in the applications of transcriptional signatures to tumor tissues sampled from different tumor sites
por: Cheng, Jun, et al.
Publicado: (2017)

An individualized prognostic signature and multi-omics distinction for early stage hepatocellular carcinoma patients with surgical resection
por: Ao, Lu, et al.
Publicado: (2016)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Individualized analysis reveals CpG sites with methylation aberrations in almost all lung adenocarcinoma tissues
por: Yan, Haidan, et al.
Publicado: (2017)

Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)

A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources
por: Zhao, Wenyuan, et al.
Publicado: (2016)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Transcriptional Signatures of Hippocampal Tau Pathology in Primary Age-Related Tauopathy and Alzheimer’s Disease
por: Stein-O’Brien, Genevieve L, et al.
Publicado: (2023)

Identification of Genes Universally Differentially Expressed in Gastric Cancer
por: Shi, Yidan, et al.
Publicado: (2021)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis
por: Tsuji, S, et al.
Publicado: (2012)

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
por: Vauthey, J-N, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kohqofhalsgp2vfa6gri3mk29g